2025 annual financial data
TScan Therapeutics 2025 Operating margin
Direct answer
Operating margin was -1,315.38%.
Operating income was -135,813,000 USD and net income was -129,766,000 USD.
Operating cash flow was -135,319,000 USD.
Get free TScan Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 10,325,000 USD
- Operating income
- -135,813,000 USD
- Net income
- -129,766,000 USD
- Operating cash flow
- -135,319,000 USD